Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Leukemia and Lymphoma

• Publication date

  1996-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428199609093433PMID 9172800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia.

  2009cited by this paper
• Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy

  2004cited by this paper
• Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia.

  1996cited by this paper
• Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study.

  1995cited by this paper
• Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.

  1995cited by this paper
• Isolation of Human cDNAs That Restore Methotrexate Sensitivity and Reduced Folate Carrier Activity in Methotrexate Transport-defective Chinese Hamster Ovary Cells (*)

  1995cited by this paper
• Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization.

  1995cited by this paper
• Isolation of a Human cDNA That Complements a Mutant Hamster Cell Defective in Methotrexate Uptake (*)

  1995cited by this paper
• Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.

  1995cited by this paper
• Molecular cloning of the human placental folate transporter.

  1995cited by this paper
• Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake.

  1994cited by this paper
• Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients.

  1994cited by this paper
• Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

  1994cited by this paper
• Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia

  1994cited by this paper
• A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells.

  1994cited by this paper
• Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.

  1994cited by this paper
• Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.

  1993cited by this paper
• Acquisition of Resistance to Antifolates Caused by Enhanced γ-Glutamyl Hydrolase Activity

  1993cited by this paper
• Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.

  1993cited by this paper
• Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.

  1992cited by this paper
• Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.

  1992cited by this paper
• Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

  1992cited by this paper
• Hyperdiploid (47-50) acute lymphoblastic leukemia in children.

  1992cited by this paper
• Progress against childhood cancer: the Pediatric Oncology Group experience.

  1992cited by this paper
• Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study.

  1992cited by this paper
• Down syndrome and leukemia.

  1992cited by this paper
• Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.

  1992cited by this paper
• Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines.

  1991cited by this paper
• Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport.

  1991cited by this paper
• Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.

  1990cited by this paper
• Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis.

  1990cited by this paper
• Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.

  1989cited by this paper
• Resistance to methotrexate and multidrug resistance in childhood malignancies.

  1989cited by this paper
• Central nervous system pharmacology of antileukemic drugs.

  1989cited by this paper
• Inhibition of folate-dependent enzymes by 7-OH-methotrexate.

  1988cited by this paper
• Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.

  1988cited by this paper
• Interactions between 7-hydroxymethotrexate and folinic acid in RAJI cells, in vitro.

  1988cited by this paper
• Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity

  1987cited by this paper
• Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry.

  1987cited by this paper
• Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

  1987cited by this paper
• Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis.

  1987cited by this paper
• A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia

  1987cited by this paper
• Methotrexate polyglutamate synthesis in lymphoblasts from children with acute lymphoblastic leukemia.

  1987cited by this paper
• Mammalian folylpoly-gamma-glutamate synthetase. 3. Specificity for folate analogues.

  1987cited by this paper
• Methotrexate bioavailability after oral and intramuscular administration in children.

  1987cited by this paper
• Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells.

  1987cited by this paper
• The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue.

  1987cited by this paper
• Flow cytometric studies of methotrexate resistance in human squamous carcinoma cell cultures.

  1987cited by this paper
• Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

  1986cited by this paper
• The cellular pharmacology of methotrexate.

  1985cited by this paper
• Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.

  1985cited by this paper
• Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer.

  1985cited by this paper
• Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

  1985cited by this paper
• A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates.

  1984cited by this paper
• Gene amplification, drug resistance, and cancer.

  1984cited by this paper
• Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture.

  1984cited by this paper
• A new fluorescent dihydrofolate reductase probe for studies of methotrexate resistance.

  1982cited by this paper
• Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.

  1982cited by this paper
• Quantitation of dihydrofolate reductase in individual parental and methotrexate-resistant murine cells. Use of a fluorescence activated cell sorter.

  1978cited by this paper
• Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.

  1976cited by this paper
• 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

  1976cited by this paper
• Drug response, dihydrofolate reductase, and cytogenetics of amethopterin-resistant Chinese hamster cells in vitro.

  1972cited by this paper
• Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

  1968cited by this paper
• Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells.

  1962cited by this paper
• Acute childhood leukemia: a ten-year study.

  1960cited by this paper
• Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

  1948cited by this paper

• L-Citrulline Improves Recovery of Enterocytes While Not Affecting Gut Microbiota in an In Vitro Model of Chemotherapy-Induced Gastrointestinal Mucositis

  2025cites this paper
• Simultaneous Determination of Methotrexate and 7-Hydroxy-Methotrexate by UHPLC-MS3 Assay Coupled With Multiple Stage Fragmentation to Enhance Sensitivity.

  2024cites this paper
• Association of GGH Promoter Methylation Levels with Methotrexate Concentrations in Chinese Children with Acute Lymphoblastic Leukemia

  2020cites this paper
• Targeted Co-Delivery of siRNA and Methotrexate for Tumor Therapy via Mixed Micelles

  2019cites this paper
• Development and validation of a sensitive UHPLC-MS/MS-based method for the analysis of folylpolyglutamate synthetase enzymatic activity in peripheral blood mononuclear cells: application in rheumatoid arthritis and leukemia patients.

  2019cites this paper
• Histidine catabolism is a major determinant of methotrexate sensitivity

  2018cites this paper
• Histidine catabolism is a major determinant of methotrexate sensitivity

  2018cites this paper
• Mathematical model to predict methotrexate elimination in children with acute lymphoblastic leukemia

  2014cites this paper
• disease across the major histocompatibility barrier in mice Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host

  2013cites this paper
• Synthesis and biological evaluation of novel antifolate analogs as potential anticancer treatment.

  2013cites this paper
• The role of uracil-DNA glycosylase and folate in the repair of DNA damage

  2012cites this paper
• Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

  2009cites this paper
• Constitutional aneuploidy and cancer predisposition.

  2009cites this paper
• Host factors and consequence of chemotherapy in pediatric cancer patients

  2008cites this paper
• Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors.

  2007cites this paper
• ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.

  2006cites this paper
• Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.

  2006cites this paper
• Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.

  2004cites this paper
• Pharmacogenetic studies of methotrexate and metafolin in a mouse model of severe and mild 5, 10-methylenetetrahydrofolate reductase deficiency

  2004cites this paper
• Novel antifolate drugs

  2003cites this paper
• Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

  2003cites this paper
• Quantification of the DHFR gene in blast cells of leukaemia patients by fluorescence in situ hybridisation.

  2003cites this paper
• Treatment of Relapsed Acute Lymphoblastic Leukemia

  2003cites this paper
• The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter.

  2002cites this paper
• The Human Reduced Folate Carrier Gene Is Regulated by the AP2 and Sp1 Transcription Factor Families and a Functional 61-Base Pair Polymorphism*

  2002cites this paper
• Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.

  2001cites this paper
• Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia

  2001cites this paper
• Relationship of Chromosome 21 and Acute Leukemia in Children With Down Syndrome

  2001cites this paper
• Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL‐BFM 86 chemotherapy program in an enlarged non‐high risk group of children and adolescents with non‐B‐cell acute lymphoblastic leukemia

  2000cites this paper
• Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia

  2000cites this paper
• The folic acid analogue methotrexate protects frog embryo cell membranes against damage by the potato glycoalkaloid alpha-chaconine.

  2000cites this paper
• DOWN SYNDROME AND LEUKEMIA: WHAT HAVE WE LEARNED?

  2000cites this paper
• Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia.

  1999cites this paper
• The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer.

  1999cites this paper
• Factors in Improved Survival from Paediatric Cancer

  1998cites this paper
• Structure and organization of the human reduced folate carrier gene.

  1998cites this paper
• Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy.

  1998cites this paper
• Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children.

  1997cites this paper
• The Acute Lymphoblastic Leukemias of Down Syndrome ( DS-ALL )

  year unknowncites this paper